

1 **Novel azo pyridone dyes based on dihydropyrimidinone skeleton: Synthesis, DFT study**
2 **and anticancer activity**

3 Julijana D. Tadić^a, Jelena M. Lađarević^{b,*}, Željko J. Vitnik^c, Vesna D. Vitnik^c, Tatjana P.

4 Stanojković^d, Ivana Z. Matić^d, Dušan Ž. Mijin^b

5 ^aInnovation Centre of Faculty of Technology and Metallurgy in Belgrade, Karnegijeva 4,
6 Belgrade, Republic of Serbia

7 ^bFaculty of Technology and Metallurgy, University of Belgrade, Karnegijeva 4, Belgrade,
8 Republic of Serbia

9 ^cDepartment of Chemistry, Institute of Chemistry, Technology and Metallurgy, University of
10 Belgrade, Studentski trg 12-16, Belgrade, Republic of Serbia

11 ^dInstitute of Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Republic of Serbia

12 *Corresponding author.

13 E-mail: jmirkovic@tmf.bg.ac.rs

14
15 **Abstract**

16 Seven novel azo dyes with 2-pyridone and dihydropyrimidinone moieties have been synthesized
17 and thoroughly characterized. The azo-hydrazone tautomerism has been investigated by
18 experimental and theoretical approaches. The optimizations of geometries have been performed
19 with density functional theory (DFT). The vibrational and NMR spectra were calculated and
20 correlated with experimental ones. Furthermore, quantum chemical descriptors were calculated
21 and MEP maps were plotted to determine biological reactivity of dyes. The antioxidant assay
22 evinced that **5**, **6** and **7** are promising antioxidant candidates. *In vitro* cytotoxic activity was studied
23 against three malignant cell lines: prostate adenocarcinoma (PC-3), lung carcinoma (A549) and

24 chronic myelogenous leukemia (K562), as well as against human normal lung fibroblasts (MRC-
25 5), using MTT assay. Examination of cytotoxic effects on human cancer cell lines showed the
26 concentration dependent cytotoxicity of all investigated compounds. The K562 cells were the most
27 sensitive to the cytotoxicity of the compounds **3**, **5** and **6**, wherein compound **5** was particularly
28 prominent and selective in cytotoxic action between K562 (24.97 μ M) and PC-3 (48.98 μ M)
29 cancer cells, and normal MRC-5 (91.11 μ M) cells. Moreover, the cell cycle analysis of compound
30 **5** was examined in K562 cells, by flow cytometry, to study its mechanism of anticancer action.
31 Finally, *in silico* evaluation of physicochemical parameters, druglikeness and ADME properties
32 showed that investigated compounds are orally bioavailable with no permeation to the blood brain
33 barrier.

34 Keywords: Biginelli adduct, azo-hydrazone tautomerism, antitumor, cell cycle arrest, ADME

35 **1. Introduction**

36 Azo dyes are the most significant class of colored synthetic compounds. They have diverse
37 application in various fields of science and industry, regarding their simple preparation and a broad
38 spectrum of derivatives [1]. The synthesis of azo dyes based on heterocycle moieties has gained
39 particular attention in last several decades [2,3]. Namely, the heterocyclic azo compounds exhibit
40 antibacterial [4], antifungal [5], antioxidant [6], analgesic [7], anti-inflammatory [8], antitubercular
41 [9] and anticancer properties [10, 11]. Moreover, studies on new antitumor drugs have revealed that
42 some azo compounds manifest cytotoxic action against EAC (Ehrlich-Lette ascites carcinoma),
43 MCF-7 and MDA-MB-231 (breast cancer), PC-3 (human prostate cancer) and K562 (myelogenous
44 leukemia) tumor cells [12].

45 Among this class of azo dyes, those with 2-pyridone moiety in the structure are particularly
46 significant. Besides their remarkable coloration properties [13], azo pyridone dyes exhibit

47 antibacterial activity [14] and demonstrate the potency for cancer therapy [15]. One of the most
48 investigated feature of azo pyridone dyes is the phenomenon of azo-hydrazone tautomerism [16-
49 18]. The structural characterization of the dyes is crucial, since the tautomeric forms differ in
50 physical properties and thus, biological activity [19].

51 On the other side, dihydropyrimidinone scaffold (DHPM or dihydropyrimidine-5-carboxylate
52 core) is a heterocyclic system which has been synthesized *via* Biginelli reaction, including one-
53 pot multicomponent reaction of an aromatic aldehyde, urea and ethyl acetoacetate [20]. The
54 Biginelli synthesis is exceptionally attractive allowing development of numerous DHPM
55 derivatives by simple variation of the starting components [21]. Furthermore, the compounds
56 based on the dihydropyrimidine-5-carboxylate core have shown remarkable biological properties
57 such as antibacterial, antiviral, antiinflammatory, antioxidant and antitumor activity [22].
58 Recently, DHPM based compounds have emerged as the calcium channel blockers, potential
59 therapeutics against Alzheimer's disease, potential new AIDS therapy, the antihypertensive agents
60 and potent breast cancer therapy [23].

61 In this manner, we merged dihydropyrimidinone based core with seven different 2-pyridones *via*
62 reaction of diazo coupling, designing a novel series of azo pyridone dyes. Since 2-pyridone and
63 DHPM moieties manifest biological activity, their conjugation can ameliorate biological
64 properties of azo dyes. Contrary to the traditional arylazo dyes, where aniline-based compounds
65 are the most commonly employed as diazotization agenesis, hereby, we use the Biginelli adduct.
66 The substitution of aryl diazonium salts with DHPM-diazo moiety, leads to elimination of highly
67 toxic degradation products of azo dyes, since Biginelli adducts exhibit negligible toxicity [24].
68 Besides, there are only few studies of DHPM-azo dyes [25,26], and according to our best
69 knowledge, DHPM-azo pyridone dyes have been unexplored. Nevertheless, cancer is one of the

70 main targets in therapeutic chemistry, so we made an effort to design azo molecules with potential
71 anticancer activity.

72 Herein, the synthesis, structural characterization and azo-hydrazone tautomerism of seven novel
73 DHPM-azo pyridone dyes have been reported. The structures of molecules have been confirmed
74 by ATR-FTIR, NMR, UV-Vis, MS and elemental analysis. The calculated structural and
75 spectroscopic properties of dyes have been investigated with density functional theory (DFT). The
76 calculated vibrational spectrum of the hydrazone tautomer has been correlated with the
77 experimental one. The nuclear magnetic resonance (NMR) chemical shifts of the hydrazone
78 tautomer have been calculated and compared with experimental data. Molecular Electrostatic
79 Potential (MEP) surfaces are plotted over the optimized geometry to brighten the reactivity of
80 investigated molecules. Furthermore, the biological reactivity of novel azo molecules has been
81 correlated with 14 quantum chemical descriptors. The antioxidant activity has been evaluated by
82 ABTS (2,2'-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid)) assay. *In vitro* antitumor action of
83 dihydropyrimidinone (**B2**, Figure 1) and DHPM-azo dyes (**1-7**, Figure 1) was determined against
84 following tumor cell lines: prostate adenocarcinoma (PC-3), lung carcinoma (A549), chronic
85 myelogenous leukemia (K562), and human normal lung fibroblast (MRC-5) using microculture
86 tetrazolium test (MTT) assay. Additionally, cell cycle analysis of the most active compound (**5**,
87 Figure 1) was examined in K562 cells in order to enlighten the antitumor properties. The effect of
88 dye **5** on the cell cycle was measured by flow cytometry. Finally, physicochemical parameters,
89 druglikeness and ADME properties of novel compounds were evaluated *in silico* by SwissADME
90 and Vega 22.


91 **2. Experimental part**

92 *2.1. Materials and Measurements*

93 All starting materials were purchased from Merck, Fluka and Acros, and were used without further
94 purification. The microwave-assisted organic synthesis was performed on Anton Paar Monowave
95 300. The chemical structures of the synthesized compounds were confirmed by melting points,
96 elemental analysis, ATR-FTIR, ¹H-NMR, ¹³C NMR, ESI-MS and UV-Vis spectral data. The
97 melting points were determined in capillary tubes on an automated melting point system Stuart
98 SMP30. Elemental analysis was done on Vario EL III elemental analyzer. Fourier transform
99 infrared spectroscopy (FT-IR) spectra of the dyes were recorded in absorbance mode, using a
100 Nicolet™ iS™ 10 FT-IR Spectrometer (Thermo Fisher Scientific) with Smart iTR™ Attenuated
101 Total Reflectance (ATR) sampling accessories. The ATR-FTIR spectra were recorded in the 500–
102 4000 cm⁻¹ range with 20 scans per spectrum. The ¹H-NMR and ¹³C NMR spectral measurements
103 were performed on a Bruker Ascend 400 instrument (400 Hz and 100 MHz, respectively) in
104 deuterated dimethylsulfoxide (DMSO-*d*₆) and deuterated trifluoroacetic acid for **7** (CF₃COOD).
105 The chemical shifts were expressed in ppm values referenced to tetramethylsilane (TMS).
106 Quadrupole ion trap mass spectrometer (LCQ Advantage (Thermo Fisher Scientific, USA) was
107 used for the compounds detection. The electrospray ionization technique (ESI) was used and
108 compounds were analyzed in the positive and negative ionization mode. The optimal source
109 working parameters for monitoring ions in positive and negative mode were: source voltage – 4.5
110 kV, sheath gas – 28 au, *i.e.* 28 arbitrary units, auxiliary gas – 4 au, capillary temperature – 220 °C
111 and capillary voltage 3 V for ESI+, or – 26 V for ESI-. The ultraviolet-visible (UV-Vis) absorption
112 spectra were recorded in ethanol, on a Shimadzu 1700 spectrophotometer, at concentration 4 ×
113 10⁻⁵ mol L⁻¹. All spectroscopic measurements were carried out at room temperature (25 °C).

114 2.2. Synthesis

115 To the best of our knowledge, synthesis of azo pyridone dyes with dihydropyrimidinone moiety,
 116 has not been reported in literature. In this study seven novel DHPM-azo dyes were obtained by
 117 following synthetic pathway given in Figure 1. In the first step, synthesis of ethyl 6-methyl-4-(4-
 118 nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (**B1**) was performed according to
 119 modified literature procedure, wherein the reaction time was elongated in regard to the reported
 120 method [21]. Second step includes the reduction of **B1** in order to produce Biginelli adduct 4-(4-
 121 aminophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (**B2**) [27]. In the third
 122 step, seven different 6-hydroxy-2-pyridones (**P1-7**) were obtained using literature methods [28,
 123 29] (the synthetic details are given in Supplementary material). Finally, seven novel azo dyes **1-7**
 124 were synthesized *via* diazotization reaction of dihydropyrimidinone (**B2**) followed by coupling
 125 reaction, of the resulting diazonium salt (**B3**), with corresponding pyridones (**P1-7**).



126

127

Figure 1. The synthetic pathway of novel DHPM-azo pyridone dyes.

128 2.2.1. Synthesis of ethyl 6-methyl-4-(4-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-
129 carboxylate (**B1**)

130 Ethyl acetoacetate (**a**) (4 mmol, 0.510 ml), 4-nitrobenzaldehyde (**b**) (4 mmol, 0.604 g) and urea
131 (**c**) (4 mmol, 0.240 g) were dissolved in 10 ml of ethanol, and 4 drops of hydrochloric acid were
132 added (Figure 1). The reaction mixture was heated in the microwave reactor at 120 °C for 30
133 minutes. When the reaction was completed, the obtained mixture was left at 4 °C for 24 hours. The
134 crude product was filtered on a Buchner funnel, washed with ethanol, air dried and then
135 recrystallized from ethanol. The structure of **B1** was confirmed by ATR-FTIR and NMR analysis,
136 and has been in accordance with literature data [21]: white crystals; yield 68 %; m.p. 204–205 °C;
137 ATR-FTIR (ν/cm^{-1}): 3225 (NH), 3111 (NH), 1720 (CO), 1636 (CO); ^1H NMR (400 MHz, DMSO-
138 d_6 , δ/ppm): 1.10 (3H, t, $J = 7.2$ Hz, $\text{COOCH}_2\text{CH}_3$), 2.27 (3H, s, CH_3), 3.99 (2H, q, $J = 7.2$ Hz,
139 $\text{COOCH}_2\text{CH}_3$), 5.27 (1H, d, $J = 2.8$ Hz, C–H), 7.51 (2H, d, $J = 8.8$ Hz, Ar–H), 7.91 (1H, s, NH),
140 8.23 (2H, d, $J = 8.4$ Hz, Ar–H), 9.38 (1H, s, NH); ^{13}C NMR (200 MHz, DMSO- d_6 , δ/ppm): 14.53
141 ($\text{COOCH}_2\text{CH}_3$), 18.35 (CH_3), 54.13 (C–H), 59.87 ($\text{COOCH}_2\text{CH}_3$), 98.62 (C– $\text{COOCH}_2\text{CH}_3$,
142 DHPM), 124.33 (Ar), 128.13 (Ar), 147.18 (Ar), 149.88 (Ar), 152.21 (C– CH_3 , DHPM), 152.46
143 (CO, DHPM), 165.22 ($\text{COOCH}_2\text{CH}_3$).

144 2.2.2. Synthesis of ethyl 4-(4-aminophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-
145 carboxylate (**B2**)

146 **B1** (2 mmol, 0.670 g) was dissolved in 40 ml of methanol and its reduction was carried out by the
147 addition of zinc (20 mmol, 1.438 g) and aqueous solution of ammonium chloride (4 mmol, 0.235
148 g in 4 ml of water). The reaction was followed by TLC, and conducted at reflux for 5 hours. The
149 reaction mixture was filtered and the filtrate was left at 4 °C for 24 hours. The resulting **B2** was
150 separated on a Buchner funnel, washed with ethanol, air dried and recrystallized from ethanol:

151 white crystals; yield 62 %; m.p. 212–213 °C; ATR-FTIR (ν/cm^{-1}): 3531, 3383 (NH₂), 3211 (NH),
152 3104 (NH), 1681 (CO), 1635 (CO); ¹H NMR (400 MHz, DMSO-*d*₆, δ/ppm): 1.11 (3H, t, *J* = 7.2
153 Hz, COOCH₂CH₃), 2.22 (3H, s, CH₃), 3.98 (2H, q, *J* = 7.2 Hz, COOCH₂CH₃), 4.97 (1H, s, C–H),
154 4.98 (2H, s, NH₂), 6.47 (2H, d, *J* = 8 Hz, Ar–H), 6.88 (2H, d, *J* = 8 Hz, Ar–H), 7.52 (1H, s, NH),
155 9.03 (1H, s, NH); ¹³C NMR (200 MHz, DMSO-*d*₆, δ/ppm): 14.59 (COOCH₂CH₃), 18.17 (CH₃),
156 54.02 (C–H), 59.49 (COOCH₂CH₃), 100.48 (C–COOCH₂CH₃, DHPM), 114.01 (Ar), 127.72 (Ar),
157 132.77 (Ar), 147.78 (Ar–NH₂), 148.30 (C–CH₃, DHPM), 152.70 (CO, DHPM), 165.99
158 (COOCH₂CH₃); Anal. Calcd for C₁₄H₁₇N₃O₃ (275.30): C, 61.08; H, 6.22; N, 15.26%; Found: C,
159 61.18; H, 6.35; N, 15.37%; ESI-MS *m/z* calc. 275.13, found (positive mode): 276.08 [M+H]⁺,
160 550.95 [2M+H]⁺, 572.92 [2M+Na]⁺.

161 2.2.3. Synthesis of DHPM-azo pyridone dyes

162 **B2** (1 mmol, 0.275 g) was dissolved in the diluted hydrochloric acid (3 ml of HCl (37% w/w) and
163 60 ml of water) and then cooled to 0–5 °C. Sodium nitrite (1.1 mmol, 0.0759 g) was dissolved in
164 cold water (4 ml) and added dropwise to a solution of **B2**. The mixture was stirred in an ice bath
165 for 1 hour in order to obtain diazonium chloride (**B3**). The corresponding 6-hydroxy-2-pyridone
166 (**P1-7**) (1 mmol) was dissolved in an aqueous solution of potassium hydroxide (1 mmol, 0.056 g
167 and 10 ml of water) and then cooled to 0–5 °C. The obtained diazonium chloride (**B3**) was added
168 dropwise to the corresponding pyridone solution. The resulting reaction mixture was stirred for 3
169 hours and maintained at 0–5 °C. When the reaction was completed the obtained azo dyes (**1-7**)
170 were filtered on a Buchner funnel, washed with water, air dried and recrystallized from ethanol.
171 All obtained dyes are characterized by melting points, ATR-FTIR, UV-Vis, ESI-MS, ¹H and ¹³C
172 NMR spectra and elemental analysis. In addition, the NMR analysis of dye **7** was performed in

173 CF₃COOD, due to the low solubility in DMSO-*d*₆. The ATR-FTIR, ESI-MS ¹H and ¹³C NMR
174 spectra for all dyes are provided in Supplementary material (Figures S1-S35).

175 *Ethyl 4-(4-((5-cyano-2-hydroxy-4-methyl-6-oxo-1,6-dihydropyridin-3-yl)diazanyl)phenyl)-6-*
176 *methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1)*. Dark orange powder; yield 73%;
177 m.p. 249-250 °C; ATR-FTIR (ν/cm⁻¹): 3296 (NH), 3211 (NH), 2219 (CN), 1674 (CO), 1622 (CO),
178 1506 (NH); ¹H NMR (400 MHz, DMSO-*d*₆, δ/ppm): 1.10 (3H, t, *J* = 7 Hz, COOCH₂CH₃), 2.26
179 (3H, s, CH₃ DHPM), 2.51 (3H, s, CH₃ Py), 3.99 (2H, q, *J* = 7 Hz, COOCH₂CH₃), 5.17 (1H, d, *J* =
180 3.2 Hz, C–H), 7.33 (2H, d, *J* = 8.2 Hz, Ar–H), 7.64 (2H, d, *J* = 8.2 Hz, Ar–H), 7.79 (1H, s, NH),
181 9.25 (1H, s, NH), 12.02 (1H, s, NH Py), 14.58 (1H, s, NH hydrazone); ¹³C NMR (200 MHz,
182 DMSO-*d*₆, δ/ppm): 14.58 (COOCH₂CH₃), 16.92 (CH₃, Py), 18.27 (CH₃, DHPM), 54.04 (C–H,
183 DHPM), 59.73 (COOCH₂CH₃), 99.38 (C–COOCH₂CH₃, DHPM), 101.09 (CN), 115.59 (C–CN),
184 117.95 (Ar), 124.04 (C=N, Py), 128.17 (Ar), 140.73 (Ar), 144.04 (Ar), 149.13 (C–CH₃, DHPM),
185 152.45 (CO, DHPM), 160.95 (Py), 161.32 (CO, Py), 161.97 (CO, Py), 165.72 (COOCH₂CH₃);
186 Anal. Calcd for C₂₁H₂₀N₆O₅ (436.42): C, 57.79; H, 4.62; N, 19.26%; Found: C, 57.99; H, 4.92; N,
187 19.36%; ESI-MS *m/z* calc. 436.15, found (negative mode): 435.22 [M–H]⁻; UV-Vis (EtOH)
188 (λ_{max}/nm (log ε/mol⁻¹dm³cm⁻¹)): 439.0 (4.55).

189 *Ethyl 4-(4-((5-cyano-2-hydroxy-1-(2-hydroxyethyl)-4-methyl-6-oxo-1,6-dihydropyridin-3-*
190 *yl)diazanyl)phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (2)*. Orange
191 powder; yield 71%; m.p. 195–196 °C; ATR-FTIR (ν/cm⁻¹): 3243 (NH), 2218 (CN), 1678 (CO),
192 1626 (CO), 1500 (NH); ¹H NMR (400 MHz, DMSO-*d*₆, δ/ppm): 1.11 (3H, t, *J* = 6.8 Hz,
193 COOCH₂CH₃), 2.27 (3H, s, CH₃ DHPM), 2.54 (3H, s, CH₃ Py), 3.56 (2H, t, *J* = 6 Hz, CH₂CH₂OH),
194 3.94–4.03 (4H, m, CH₂CH₂OH, COOCH₂CH₃), 5.18 (1H, d, *J* = 2.8 Hz, C–H), 7.35 (2H, d, *J* =
195 8.8 Hz, Ar–H), 7.70 (2H, d, *J* = 8.8 Hz, Ar–H), 7.77 (1H, d, *J* = 2 Hz, NH), 9.24 (1H, s, NH), 14.60

196 (1H, s, NH hydrazone); ¹³C NMR (200 MHz, DMSO-*d*₆, δ/ppm): 14.58 (COOCH₂CH₃), 16.77
197 (CH₃, Py), 18.27 (CH₃, DHPM), 41.92 (CH₂CH₂OH), 54.05 (C-H), 57.91 (CH₂CH₂OH), 59.72
198 (COOCH₂CH₃), 99.42 (C-COOCH₂CH₃), 100.88 (CN), 115.60 (C-CN), 118.16 (Ar), 123.51
199 (C=N, Py), 128.16 (Ar), 140.77 (Ar), 144.18 (Ar), 149.13 (C-CH₃, DHPM), 152.46 (CO, DHPM),
200 159.60 (Py), 160.66 (CO, Py), 161.18 (CO, Py), 165.73 (COOCH₂CH₃); Anal. Calcd for
201 C₂₃H₂₄N₆O₆ (480.47): C, 57.49; H, 5.03; N, 17.49%; Found: C, 57.79; H, 5.15; N, 17.69%; ESI-
202 MS m/z calc. 480.18, found (positive mode): 503.12 [M+Na]⁺, 982.81 [2M+Na]⁺, found (negative
203 mode): 479.26 [M-H]⁻; UV-Vis (EtOH) (λ_{max}/nm (log ε/mol⁻¹dm³cm⁻¹)): 440.0 (4.50).

204 *Ethyl* 4-(4-((5-cyano-2-hydroxy-4-methyl-6-oxo-1-propyl-1,6-dihydropyridin-3-
205 yl)diazanyl)phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (3). Orange
206 powder; yield 65%; m.p. 160–161 °C; ATR-FTIR (ν/cm⁻¹): 3593 (NH), 3507 (NH), 3220 (NH),
207 2233 (CN), 1709 (CO), 1677 (CO), 1621 (CO), 1514 (NH); ¹H NMR (400 MHz, DMSO-*d*₆,
208 δ/ppm): 0.89 (3H, t, *J* = 7.6 Hz, CH₂CH₂CH₃), 1.11 (3H, t, *J* = 6.8 Hz, COOCH₂CH₃), 1.58 (2H,
209 m, CH₂CH₂CH₃), 2.27 (3H, s, CH₃ DHPM), 2.54 (3H, s, CH₃ Py), 3.82 (2H, t, *J* = 7.2 Hz,
210 CH₂CH₂CH₃), 4.00 (2H, q, *J* = 7.2 Hz, COOCH₂CH₃), 5.18 (1H, d, *J* = 2.8 Hz, C-H), 7.34 (2 H,
211 d, *J* = 8.4 Hz, Ar-H), 7.70 (2H, d, *J* = 8.4 Hz, Ar-H), 7.77 (1H, s, NH), 9.23 (1H, s, NH), 14.62
212 (1H, s, NH hydrazone); ¹³C NMR (200 MHz, DMSO-*d*₆, δ/ppm): 11.71 (CH₂CH₂CH₃), 14.58
213 (COOCH₂CH₃), 16.79 (CH₃, Py), 18.27 (CH₃, DHPM), 20.96 (CH₂CH₂CH₃), 41.3 (CH₂CH₂CH₃),
214 54.06 (C-H), 59.72 (COOCH₂CH₃), 99.41 (C-COOCH₂CH₃), 100.78 (CN), 115.60 (C-CN),
215 118.17 (Ar), 123.48 (C=N, Py), 128.16 (Ar), 140.78 (Ar), 144.20 (Ar), 149.14 (C-CH₃, DHPM),
216 152.45 (CO, DHPM), 159.68 (Py), 160.57 (CO, Py), 161.04 (CO, Py), 165.73 (COOCH₂CH₃);
217 Anal. Calcd for C₂₄H₂₆N₆O₅ (478.50): C, 60.24; H, 5.48; N, 17.56%; Found: C, 60.49; H, 5.63; N,

218 17.78%; ESI-MS m/z calc. 478.20, found (negative mode): 477.18 $[M-H]^-$. UV-Vis (EtOH)
219 (λ_{\max}/nm ($\log \epsilon/mol^{-1}dm^3cm^{-1}$)): 442.0 (4.52).

220 *Ethyl* 4-(4-((5-cyano-2-hydroxy-4-methyl-6-oxo-1-phenyl-1,6-dihydropyridin-3-
221 yl)diazenyl)phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (**4**). Dark orange
222 powder, 70%, m.p. 243–244 °C; ATR-FTIR (ν/cm^{-1}): 3248 (NH), 2219 (CN), 1678 (CO), 1629
223 (CO), 1503 (NH). 1H NMR (400 MHz, DMSO- d_6 , δ/ppm): 1.11 (3H, t, $J = 7.2$ Hz, COOCH $_2$ CH $_3$),
224 2.26 (3H, s, CH $_3$ DHPM), 2.62 (3H, s, CH $_3$ Py), 4.00 (2H, q, $J = 6.8$ Hz, COOCH $_2$ CH $_3$), 5.17 (1H,
225 d, $J = 2.4$ Hz, C-H), 7.28–7.34 (4H, m, Ar), 7.46–7.69 (5H, m, Phenyl substituent), 7.76 (1H, s,
226 NH), 9.23 (1H, s, NH), 14.49 (1H, s, NH hydrazone). ^{13}C NMR (200 MHz, DMSO- d_6 , δ/ppm):
227 14.58 (COOCH $_2$ CH $_3$), 16.95 (CH $_3$, Py), 18.27 (CH $_3$, DHPM), 54.04 (C-H), 59.72 (COOCH $_2$ CH $_3$),
228 99.40 (C–COOCH $_2$ CH $_3$), 101.20 (CN), 115.58 (C–CN), 118.12 (Ar), 123.88 (C=N, Py), 128.16
229 (Ar), 129.10 (Ar, Phenyl substituent), 129.32 (Ar, Phenyl substituent), 129.43 (Ar, Phenyl
230 substituent), 134.59 (Ar, Phenyl substituent), 140.79 (Ar), 144.19 (Ar), 149.14 (C–CH $_3$, DHPM),
231 152.45 (CO, DHPM), 160.18 (Py), 160.65 (CO, Py), 161.11 (CO, Py), 165.73 (COOCH $_2$ CH $_3$);
232 Anal. Calcd for C $_{27}$ H $_{24}$ N $_6$ O $_5$ (512.52): C, 63.27; H, 4.72; N, 16.40%; Found: C, 63.49; H, 4.95; N,
233 16.51%; ESI-MS m/z calc. 512.18, found (negative mode): 511.18 $[M-H]^-$, found (positive mode):
234 513.17 $[M+H]^+$; UV-Vis (EtOH) (λ_{\max}/nm ($\log \epsilon/mol^{-1}dm^3cm^{-1}$)): 443.0 (4.58).

235 *Ethyl* 4-(4-((5-cyano-2-hydroxy-6-oxo-4-phenyl-1,6-dihydropyridin-3-yl)diazenyl)phenyl)-6-
236 methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (**5**). Dark orange powder; yield 61%;
237 m.p. 275–276 °C; ATR-FTIR (ν/cm^{-1}): 3405 (NH), 3210 (NH), 2229 (CN), 1693 (CO), 1652 (CO),
238 1505 (NH). 1H NMR (400 MHz, DMSO- d_6 , δ/ppm): 1.07 (3H, t, $J = 7,2$ Hz, COOCH $_2$ CH $_3$), 2.24
239 (3H, s, CH $_3$ DHPM), 3.97 (2H, q, $J = 8$ Hz, COOCH $_2$ CH $_3$), 5.11 (1H, d, $J = 3,2$ Hz, C-H), 7.20–
240 7.26 (4H, m, Ar–H), 7.51–7.59 (5H, m, Phenyl substituent), 7.69 (1H, s, NH), 9.18 (1H, s, NH),

241 12.19 (1H, s, NH pyrimidine), 14.60 (1H, s, NH hydrazone). ^{13}C NMR (200 MHz, DMSO- d_6 ,
242 δ/ppm): 14.54 (COOCH $_{2\text{C}}$ H $_3$), 18.29 (CH $_3$, DHPM), 54.04 (C-H), 59.68 (COOCH $_{2\text{C}}$ H $_3$), 99.23
243 (C-COOCH $_{2\text{C}}$ H $_3$), 100.64 (CN), 115.73 (C-CN), 117.65 (Ar), 124.05 (C=N, Py), 128.11 (Ar),
244 128.32 (Ar), 129.91 (Ar, Phenyl substituent), 130.47 (Ar, Phenyl substituent), 133.35 (Ar, Phenyl
245 substituent), 140.73 (Ar), 144.02 (Ar), 149.15 (C-CH $_3$, DHPM), 152.35 (CO, DHPM), 161.35
246 (Py), 161.46 (CO, Py), 162.16 (CO, Py), 165.69 (COOCH $_{2\text{C}}$ H $_3$); Anal. Calcd for C $_{26}$ H $_{22}$ N $_6$ O $_5$
247 (498.49): C, 62.64; H, 4.45; N, 16.86%; Found: C, 62.80; H, 4.66; N, 16.91%; ESI-MS m/z calc.
248 498.17, found (negative mode): 497.19 [M-H] $^-$. UV-Vis (EtOH) ($\lambda_{\text{max}}/\text{nm}$ (log $\epsilon/\text{mol}^{-1}\text{dm}^3\text{cm}^{-1}$):
249 442.5 (4.58).

250 *Ethyl 4-(4-((5-carbamoyl-2-hydroxy-4-methyl-6-oxo-1,6-dihydropyridin-3-yl)diazanyl)phenyl)-6-*
251 *methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (6)*. Orange solid; yield 61%; m.p. 201-
252 203 °C. ATR-FTIR (ν/cm^{-1}): 3248 (NH), 1684 (CO), 1648 (CO), 1513 (NH). ^1H NMR (400 MHz,
253 DMSO- d_6 , δ/ppm): 1.11 (3H, t, $J = 7$ Hz, COOCH $_{2\text{C}}$ H $_3$), 2.22 (3H, s, CH $_3$ DHPM), 2.26 (3H, s,
254 CH $_3$ DHPM), 3.99 (2H, q, $J = 7$ Hz, COOCH $_{2\text{C}}$ H $_3$), 5.15 (1H, d, $J = 2.4$ Hz, C-H), 7.28 (2H, d, J
255 = 8.2 Hz, Ar-H), 7.50–7.52 (3H, m, Ar-H and CONH $_2$), 7.69 (1H, s, CONH $_2$), 7.79 (1H, s, NH),
256 9.22 (1H, s, NH), 11.66 (1H, s, NH Py), 14.23 (1 H, s, NH hydrazone). ^{13}C NMR (200 MHz,
257 DMSO- d_6 , δ/ppm): 14.59 (COOCH $_{2\text{C}}$ H $_3$), 14.75 (CH $_3$, Py), 18.26 (CH $_3$, DHPM), 54.01 (C-H),
258 59.70 (COOCH $_{2\text{C}}$ H $_3$), 99.57 (C-COOCH $_{2\text{C}}$ H $_3$), 116.49 (C-CN), 116.69 (Ar), 126.23 (C=N, Py),
259 128.06 (Ar), 141.38 (Ar), 145.78 (Ar), 148.94 (C-CH $_3$, DHPM), 152.51 (CO, DHPM), 162.19
260 (Py), 162.22 (CO, Py), 162.42 (CO, Py), 165.76 (COOCH $_{2\text{C}}$ H $_3$), 166.81 (CONH $_2$); Anal. Calcd
261 for C $_{21}$ H $_{22}$ N $_6$ O $_6$ (454.44): C, 55.50; H, 4.88; N, 18.49%; Found: C, 55.69; H, 4.92; N, 18.63%;
262 ESI-MS m/z calc. 454.16, found (negative mode): 453.19 [M-H] $^-$, found (positive mode): 454.99

263 $[M+H]^+$, found (positive mode): 477.11 $[M+Na]^+$; UV-Vis (EtOH) (λ_{\max}/nm (log
264 $\epsilon/\text{mol}^{-1}\text{dm}^3\text{cm}^{-1}$): 428.5 (4.60).

265 *Ethyl 4-(4-((2-hydroxy-4-methyl-6-oxo-5-pyridinium-1,6-dihydropyridin-3-yl)diazanyl)phenyl)-6-*
266 *methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (7)*. Red powder; yield 61%; m.p. 230-
267 232; ATR-FTIR (ν/cm^{-1}): 3382 (NH), 3233 (NH), 1690 (CO), 1616 (CO); ^1H NMR (400 MHz,
268 $\text{DMSO-}d_6$, δ/ppm): 1.11 (3H, t, $J = 7$ Hz, $\text{COOCH}_2\text{CH}_3$), 2.14 (3H, s, CH_3 Py), 2.25 (3H, s, CH_3
269 DHPM), 3.99 (2H, q, $J = 7$ Hz, $\text{COOCH}_2\text{CH}_3$), 5.14 (1H, s, C-H), 7.24 (2H, d, $J = 8$ Hz, Ar-H),
270 7.46 (2H, d, $J = 8$ Hz, Ar-H), 7.74 (1H, s, NH), 8.23 (2H, t, $J = 6.8$ Hz, Pyridinium substituent),
271 8.69 (1H, t, $J = 7.6$ Hz, Pyridinium substituent), 9.06 (2H, d, $J = 5.6$ Hz, Pyridinium substituent),
272 9.20 (1H, s, NH), 10.47 (1H, s, Py); ^{13}C NMR (200 MHz, $\text{DMSO-}d_6$, δ/ppm): 14.59
273 ($\text{COOCH}_2\text{CH}_3$), 18.26 (CH_3 , DHPM), 54.20 (C-H), 59.67 ($\text{COOCH}_2\text{CH}_3$), 99.78 (C-
274 $\text{COOCH}_2\text{CH}_3$), 127.35 (Ar), 128.31 (C=N, Py), 148.71 (Ar, Pyridinium substituent), 152.59 (CO,
275 DHPM), 165.85 (CO, $\text{COOCH}_2\text{CH}_3$); ^1H NMR (400 MHz, CF_3COOD , δ/ppm): 1.34 (3H, t, $J = 7$
276 Hz, $\text{COOCH}_2\text{CH}_3$), 2.46 (3H, s, CH_3 Py), 4.32 (2H, q, $J = 7$ Hz, $\text{COOCH}_2\text{CH}_3$), 5.76 (1H, s, C-
277 H), 7.65 (2H, d, $J = 8.8$ Hz, Ar-H), 7.75 (2H, d, $J = 8.4$ Hz, Ar-H), 8.38 (2H, d, $J = 7$ Hz,
278 Pyridinium substituent), 8.87–8.91 (3H, m, Pyridinium substituent), 10.01 (1H, s, NH), 10.82 (1H,
279 s, NH pyrimidine), 15.02 (1H, s, NH hydrazone); ^{13}C NMR (200 MHz, CF_3COOD , δ/ppm): 14.46
280 ($\text{COOCH}_2\text{CH}_3$), 14.68 (CH_3 , Py), 57.72 (C-H), 65.25 ($\text{COOCH}_2\text{CH}_3$), 104.58 (C- $\text{COOCH}_2\text{CH}_3$),
281 123.70 (C-CN), 128.32 (C=N, Py), 131.21 (Ar, Pyridinium substituent), 131.53 (Ar, DHPM),
282 143.03 (Ar, DHPM), 145.69 (Ar, DHPM), 149.40 (Ar, Pyridinium substituent), 150.94 (C- CH_3 ,
283 DHPM), 155.64 (CO, DHPM), 163.04 (Py), 170.64 (CO, $\text{COOCH}_2\text{CH}_3$); Anal. Calcd for
284 $\text{C}_{25}\text{H}_{25}\text{N}_6\text{O}_5$ (489.50): C, 61.34; H, 5.15; N, 17.17%; Found: C, 61.51; H, 5.58; N, 17.35%; ESI-

285 MS m/z calc. 498.19, found (positive mode) 489.29 [M⁺]; UV-Vis (EtOH) ($\lambda_{\text{max}}/\text{nm}$ (log
286 $\epsilon/\text{mol}^{-1}\text{dm}^3\text{cm}^{-1}$): 428.0 (4.60).

287 2.3. Computational details

288 DFT calculations of investigated dyes were performed using Gaussian 09 program package [30]
289 with B3LYP/6-311++G(d,p) method. The default convergence criteria were used without any
290 constraint on the geometry. The stability of the optimized geometry was checked by frequency
291 calculations, which gave real values for all the obtained frequencies. Optimized geometry data
292 were used in the calculations of IR and NMR spectra as well as energies of frontier molecular
293 orbitals (FMO).

294 The harmonic frequencies were calculated with B3LYP/6-311++G(d,p) method and then scaled
295 by 0.968 [31]. The assignments of the calculated wavenumbers were utilized by the animation
296 option of GaussView 5.0 graphical interface [32] from Gaussian programs, which performed a
297 visual presentation of the feature of vibration modes.

298 The nuclear magnetic resonance (NMR) chemical shifts calculations were accomplished with
299 Gauge-Independent Atomic Orbital (GIAO) method, at the same level of theory in DMSO. The
300 solvent effect was inducted with CPCM (Conductor Polarizable Continuum Model). In attempt to
301 correct the large deviation between experimental and calculated ¹H NMR shift for hydrogen in N-
302 H groups in DMSO-*d*₆, as solvent, three DMSO molecules were explicitly added in the position
303 that allowed the formation of hydrogen bonds in molecule. The ¹H and ¹³C isotropic chemical
304 shifts are presented in relation to the corresponding values for TMS. The energies of frontier
305 molecular orbitals (FMO) and molecular electrostatic potential (MEP) maps analyses helped to
306 explain reactivity of dye molecules.

307 The quantum chemical descriptors, such as the energy of the highest occupied molecular orbital
308 (E_{HOMO}), the energy of the lowest unoccupied molecular orbital (E_{LUMO}), HOMO-LUMO energy
309 gap (E_{GAP}), ionization energy (I), electron affinity (A), absolute hardness (η), absolute softness (σ),
310 optical softness (σ_o), global softness (S), absolute electronegativity (χ), chemical potential (CP),
311 electrophilicity index (ω), nucleophilicity index (N) and additional electronic charges (ΔN_{max}) were
312 calculated in water to investigate biological reactivity. The E_{HOMO} and E_{LUMO} were taken directly
313 from the calculation, while other QCDs were estimated by equations [33] given in Supplementary
314 material.

315 2.4. Antioxidant activity

316 The antioxidant activity of investigated dyes was determined by the ABTS radical-scavenging
317 assay [34]. A stock solution of the ABTS^{•+} radical cation was prepared in the reaction of ABTS
318 (4.912 mL, 7 mM in phosphate-buffered saline (PBS)) and potassium persulfate (0.088 mL, 140
319 mM in distilled water). After 16 h of incubation in the dark, the stock solution was diluted with
320 methanol until absorbance recorded at 734 nm was 0.700 ± 0.02 . Subsequently, 20 μL of the
321 methanolic dye solutions (2 mM) were mixed with 2 mL of the ABTS radical solution, shaken and
322 stored in the dark for 10 min. Afterwards the absorbance was measured at 734 nm. Each test was
323 done in triplicate. The inhibition percentage of ABTS^{•+} was calculated using the formula:

324 $\text{Inhibition (\%)} = (A_c - A_s) / A_c \times 100$, where A_c is the absorbance of the control solution (20 μL of
325 methanol in 2 mL of ABTS solution) and A_s is the absorbance of the sample solution. Ascorbic
326 acid was used as a standard antioxidant. The antioxidant ability of the most promising candidates
327 **5**, **6** and **7** was further evaluated by determination of the IC_{50} values. The methanolic solutions of
328 selected dyes and ascorbic acid were prepared at concentration ranging from 2 mM do 0.5 mM,

329 and obtained IC₅₀ were compared. The tests were performed in triplicate. Resulting IC₅₀ values are
330 presented as means with standard deviation (\pm SD) from three experiments (n = 3).

331 *2.5. In vitro cytotoxic activity*

332 The cytotoxic activity of seven novel dyes **1–7** and their precursor **B2** was examined against three
333 human cancer cell lines: prostate adenocarcinoma PC-3, lung carcinoma A549, and chronic
334 myelogenous leukemia K562, as well as on human normal lung fibroblasts MRC-5. The cytotoxic
335 evaluation of all compounds against normal cells MRC-5 was carried out to explore the toxicity
336 and selectivity of the tested compounds. All tested cell lines were obtained from the American
337 Type Culture Collection (Manassas, VA, USA). Stock solutions of the compounds were made in
338 a dimethyl sulfoxide at the concentration of 10 mM. All tested cell lines were cultured in a RPMI-
339 1640 nutrient medium which contained 2 mM L-glutamine, 100 μ g/mL streptomycin, 100 IU/mL
340 penicillin, 10% heat-inactivated (56 °C) fetal bovine serum and 25 mM HEPES, adjusted to pH
341 7.2 with a bicarbonate solution. PC-3 (5,000 cells per well), A549 (5,000 cells per well), and MRC-
342 5 cells (5,000 cells per well) were seeded into 96-well microtiter plates and the next day five
343 different concentrations of the compounds were added to the cells. K562 cells (5,000 cells per
344 well) were seeded 2 h before the addition of the compounds. The nutrient medium was added to
345 the control cells. The CDDP (cisplatin) was used as a standard reference drug. The cell survival
346 was measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
347 colorimetric assay after 72 h incubation of cells with compounds, according to the standard
348 protocol firstly described by Mosmann [35], and which was modified by Ohno and Abe [36]. The
349 experiments were repeated three times and performed in triplicate.

350 *2.4. Cell cycle analysis by flow cytometry*

351 Chronic myelogenous leukemia K562 cells were seeded into 6-well plates, and 2 hours later the
352 cells were treated with 2IC₅₀ concentration of the compound **5**. The control K562 cells were
353 cultured in a RPMI-1640 nutrient medium, as previously described. After 24 h treatment, the
354 control cells and the cells treated with compound **5** were harvested, washed in PBS and fixed in
355 70% ethanol on ice, according to standard protocol [37]. The cell samples were stored one week
356 on -20°C. Afterwards, the ethanol was removed and cells were washed in PBS. The cells were
357 treated with RNase A for 30 min at 37°C, and then stained with propidium iodide. The percentage
358 of K562 cells in the subG1, G1, S and G2/M phases of the cell cycle were determined using a BD
359 FACSCalibur flow cytometer. The analyses of acquired data (10,000 events collected for each
360 gated cell sample) were done using a CELLQuest software.

361 *2.5. In silico assessment of physicochemical and ADME properties*

362 The molecular structures of hydrazones **1–7** and zwitter ionic form **7a** (Supplementary material,
363 Figure S24) were converted into SMILES database using ChemDraw Ultra 12.0. Then, these
364 SMILES were inserted in SwissADME [38] website to calculate the physicochemical descriptors,
365 pharmacokinetic properties, ADME parameters and medicinal chemistry data. In addition, the
366 physicochemical descriptors were estimated by program Vega 22 version 2.4 [39] from previously
367 optimized geometries with B3LYP/6-311++G(d,p) method.

368 **3. Results and discussion**

369 *3.1. Synthesis*


370 Novel azo dyes **1–7** were synthesized *via* classical diazo coupling reactions between diazonium
371 salt, formed by diazotization of **B2**, and corresponding 6-hydroxy-2-pyridone **P1–7** (Figure 1).
372 The obtained azo compounds were isolated in a good yield, and their structures were confirmed
373 by ATR-FTIR, ¹H NMR, ¹³C NMR, ESI-MS, UV–Vis spectra and elemental analysis. The

374 synthesized DHPM-azo pyridone dyes **1–7**, contain hydroxy group in the *ortho*- position to the
375 azo linkage, enabling intramolecular proton transfer, and thus the existence of the azo and the
376 hydrazone tautomeric forms (Figure 1) [40].

377 The ATR-FTIR and NMR data of novel dyes **1–6** suggest the existence of the hydrazone
378 tautomeric form (Figure 1) in the solid state, as well as, in the DMSO-*d*₆ solution. The stretching
379 vibrations of the carbonyl groups appear in the ATR-FTIR spectra in the region of 1709–1616 cm⁻¹.
380 The N-H stretching vibrations of the hydrazone group appear in the region of 3210–3296 cm⁻¹.
381 Additional confirmation of the presence of the hydrazone form is intensive band appearing in the
382 region of 1514–1503 cm⁻¹ which is ascribed to mutual stretching of C=N and bending of N-H
383 vibrations. The ¹H NMR spectra of dyes **1–6**, obtained in DMSO-*d*₆ solution, contain the signal of
384 the hydrazone N-H group in the range of 14.23–14.62 ppm. The ¹³C NMR spectra confirmed the
385 presence of hydrazone form, which is evidenced by signals of two carbonyl carbons, originating
386 from pyridone moiety, in the range of 160.65–162.22 ppm (Figure 1, C6) and 161.11–164.20 ppm
387 (Figure 1, C2).

388 Exceptionally, dye **7** is found to be in a deprotonated hydrazone form (zwitter ionic form) in a
389 solid state, as well as in DMSO-*d*₆ solution (Figure S36, Supplementary material, Structure **7a**).
390 Since coupling reactions have been performed under the alkaline conditions, dye **7** can be simply
391 deprotonated during the synthesis. Namely, ¹H NMR spectrum of **7**, in DMSO-*d*₆ solution, did not
392 contain the signal of the proton resonance of hydrazone –NH group, but ¹³C NMR analysis detected
393 signal assigned to C5=N at 128.31 ppm. Also, ATR-FTIR analysis confirmed zwitter ionic
394 structure in solid state, since N-H bending vibrations, attributed to the hydrazone –NH group, have
395 not been presented in the spectrum. However, the existence of hydrazone form is confirmed by
396 NMR analysis in CF₃COOD solution. The signal of low intensity at 15.03 ppm, in ¹H NMR

397 spectrum, was ascribed to the N–H proton resonance of the hydrazone –NH group [41], and signal
398 at 128.32 ppm, in ^{13}C NMR spectrum, was ascribed to C5=N.
399 Nevertheless, the ESI-MS spectra of the dyes **1–7** showed the molecular ion peaks at the m/z values
400 corresponding to the molecular weight of the investigated dyes.
401 The UV-Vis spectra of the studied molecules in ethanol are shown in Figure 2. The obtained
402 absorption spectra suggest the existence of hydrazone tautomeric form in case of all investigated
403 dyes [16-18,41,42].




404
405 Figure 2. UV-Vis spectra of dyes **1–7** in ethanol.
406 It can be observed in Figure 2 that different substituents at the N atom, of the pyridone ring, in
407 case of dyes **1–4**, do not affect significantly the positions of the UV–Vis absorption maxima [43].
408 Also, the replacement of the methyl group, on the C4 atom of the pyridone ring, with phenyl group,
409 in case of dye **5**, does not make a notable difference in the position of the absorption maximum,
410 comparing to dyes **1–4**. However, in case of dye **6**, the replacement of the 3-cyano group, on the
411 pyridone moiety, with a weaker electron-accepting 3-amido group, causes a hypsochromic shift of
412 the absorption maximum [44]. Dye **7** carrying the pyridinium ring on the pyridone moiety has


413 absorption maximum at the lowest wavelength comparing to dyes **1–6**. This behavior is assumed
414 to be the consequence of the planarity disruption of the molecule which causes hypsochromic shift
415 of the absorption maximum.

416 *3.2. Conformational analysis*

417 The calculated energy data of possible tautomeric forms confirm that the most stable form of the
418 investigated dyes is hydrazone one for dyes **1–6**, and deprotonated hydrazone (zwitter ion) for dye
419 **7**. The optimized geometries of the most stable conformers of dye **1** obtained with B3LYP method
420 are presented in Figure 3. It can be seen that the phenylazo pyridone part of molecule is planar,
421 while the DHPM group is orthogonal to that plane, preventing electron delocalization between
422 these two parts of the molecule. The largest conformational difference in the molecule results from
423 the rotation of the DHPM group around the C14–C20 bond. The B3LYP/6-31+G(d) calculation in
424 gas phase showed that the energy barrier for this rotation is ~2.0 kcal/mol and the rotation produces
425 two conformers with almost identical energies (Figure 4). The overall process can be also done by
426 changing the torsion angle around C9–N1 bond but the rotation energy for this process is
427 significantly higher, ~6 kcal/mol, which is in line with our previously published results for same
428 bond in similar compound (Supplementary material, Figure S37) [45].




429
 430 Figure 3. The optimized geometries of the most stable conformers of dye **1** obtained with B3LYP
 431 method with used atoms numeration.
 432



433
 434 Figure 4. Potential energy surface for the rotation of the DHPM group around the C14–C20 bond
 435 of dye **1**.

436 3.3. Vibrational analysis

437 The vibration frequencies of hydrazone tautomer of dye **1** were calculated with B3LYP/6-
 438 311++G(d,p) method and the most characteristic of them are compared with experimental ones.
 439 The good correlation confirmed the hydrazone form in solid state. The visual comparison of the
 440 experimental and calculated spectrum is presented in Figure 5. The calculated and experimental
 441 vibrational frequencies of dye **1** are presented in Table 1, and numeration of the dye is given in
 442 Figure 3.



443

444

Figure 5. The experimental (a) and calculated (b) IR spectra of dye **1**.

445

446 Table 1. The observed FT-IR and calculated (B3LYP/6-311++G(d,p)) frequencies for hydrazone

447 tautomer of dye **1** [harmonic frequency (cm⁻¹), IR_{int} (K mmol⁻¹)].

Mode no.	IR exp cm ⁻¹	Unscaled B3LYP	Scaled B3LYP	IR _{int} ^a	Assignments
150	3450	3630	3514	86.75	vN25-H46
149	3430	3614	3498	37.9	vN22-H45
148	3296	3574	3460	87.46	vN6-H52
147	3211	3290	3185	99.00	vN1-H48
144	3114	3178	3076	7.45	v _{sym} CH
143	2977	3147	3046	12.1	v _{asym} CH
130	2219	2330	2255	59.5	vCN
129	1700	1785	1728	773.79	vC24=O28
128	1674	1759	1703	744.8	vC7=O18
127	1640	1743	1687	363.33	vC27=O29

126	1622	1704	1649	233.25	$\nu\text{C5=O17}$
123	1570	1624	1572	184.8	$\nu\text{C=C} + \beta\text{N1-H48}$
122	1506	1602	1551	1163.83	$\nu\text{C3=N2} + \beta\text{N1-H48}$
121	1450	1577	1527	51.96	$\nu\text{C4=C8} + \nu\text{N1-N2}$
117	1428	1496	1448	36.56	$\beta\text{N25-H46}$
112	1401	1470	1423	119.3	$\beta\text{N22-H45} + \beta\text{CH}$
109	1390	1447	1401	449.0	$\beta\text{N1-H48} + \beta\text{N6-H52}$
68	847	872	844	66.15	$\gamma\text{N1-H48}$
55	699	706	683	19.44	$\beta\text{C5=O17} + \beta\text{C7=O18}$
54	646	689	667	71.4	$\gamma\text{N6-H52}$
50	592	618	598	83.00	$\gamma\text{N22-H45} + \gamma\text{N25-H46}$

448 ^aIR_{Int} – IR intensity; K mmol⁻¹; ν – stretching; ν_{sym} symmetric stretching; ν_{asym} – asymmetric stretching; β – in-plane
449 bending; γ – out-of-plane bending.

450

451 Two broad bands at 3430 and 3450 cm⁻¹ in experimental spectrum are assigned to symmetric and
452 asymmetric stretching vibrations of two N22–H45 and N25–H46 groups of DHMP moiety, which
453 correlate with 3498 and 3514 cm⁻¹ in calculated spectrum. For hydrazone form of dye **1**, the most
454 important are two weak bands at 3211 and 3296 cm⁻¹, which belong to stretching vibrations of
455 N1–H48 and N6–H52 bonds of hydrazone and pyridone groups, respectively. These assignments
456 are supported by scaled theoretical values 3185 and 3460 cm⁻¹ (B3LYP mode nos. 147 and 148),
457 respectively, as well as with literature data. The bands centered at 2977 and 3114 cm⁻¹ in FT-IR
458 are assigned to aromatic asymmetric and symmetric C–H stretching vibrations. It can be seen from
459 Table 1 that in-plane bending vibrations of N1–H48 and N6–H52 are at 1390 cm⁻¹ and counterpart
460 in calculated spectrum is at 1401 cm⁻¹. The medium strong peaks at 646 and 847 cm⁻¹ are ascribed
461 to out-of-plane bending vibrations of N6–H52 and N1–H48 bonds, respectively. The band
462 characteristic for stretching vibrations of CN group at 2219 cm⁻¹ correlate well with calculated
463 value 2255 cm⁻¹.

464 The stretching bands of polar carbonyl groups C5=O17 and C7=O18 of pyridone and C24=O28
465 of DHMP moieties are at 1622, 1674 and 1700 cm⁻¹, respectively, and correlate well with
466 calculated values 1649, 1703 and 1728 cm⁻¹ (B3LYP mode nos. 126, 128 and 129). Vibrational

467 mode of C27=O29 of ethoxycarbonyl group is at 1640 cm^{-1} which is in accordance with the
468 theoretically scaled frequencies at 1687 cm^{-1} . The band appearing at 699 cm^{-1} in FT-IR spectrum
469 originated from in-plane bending vibrations of C5=O17 and C7=O18 of pyridone ring, and the
470 corresponding scaled calculated value is 683 cm^{-1} . The existence of stretching and bending bands
471 of carbonyl groups in FT-IR spectrum and their correlation with calculated values confirmed the
472 hydrazone tautomer of dye **1**. Additional evidence of hydrazone tautomer is stretching N1–N2 and
473 C3=N2 group vibrations appeared as intensive sharp bands at 1450 and 1506 cm^{-1} in FT-IR
474 spectrum. The band appearing at 1527 cm^{-1} has contributions from the N1–N2 and C4=C8
475 stretching vibrations in calculated spectrum. The calculated stretching vibrations of C3=N2 group
476 is coupled with in-plane-bending vibrations of N1–H48 at 1551 cm^{-1} . The out-of-plane bending
477 vibrations of four N–H groups are in the low-frequency region at 592 – 847 and 598 – 844 cm^{-1} in
478 experimental and calculated spectra, respectively. From Table 1 it is evident that experimental data
479 correlate well with the calculated data of hydrazone tautomer of **1**.

480 *3.4. NMR spectral analysis*

481 Powerful confirmation of the tautomeric structure of dyes **1**–**7** results from the analysis of their
482 NMR spectra. In this part, analysis of the most significant ^1H and ^{13}C NMR chemical shifts of dye
483 **1** is done in attempt to confirm its hydrazone tautomeric form. The calculated and experimental
484 ^1H and ^{13}C NMR chemical shifts are presented in Table 2. The recorded ^1H and ^{13}C NMR spectra
485 of **1** in DMSO- d_6 are shown in Figure S1 and S2 (Supplementary material).

486 In the experimental ^1H NMR spectrum, the chemical shift values for hydrogen of ethyl group are
487 1.1 and 3.99 ppm. Signals for two methyl groups of DHMP and pyridone moieties are at 2.26 and
488 2.51 ppm, respectively. These chemical shifts correlate well with calculated values in aliphatic
489 region 1.14 – 4.0 ppm, with respect to TMS, in DMSO solution by B3LYP/6-311++G(d,p) method.

490 The experimental peaks at 7.33–7.64 ppm are originating from aromatic hydrogen atoms. The
 491 calculated values of these peaks are in the region 7.49–8.23 ppm. Two signals of hydrogen H45
 492 and H46 of NH groups of DHMP appear at 7.79 and 9.25 ppm in experimental spectrum. They are
 493 determined at 9.34 and 10.74 ppm in calculated spectrum. The most significant signals for
 494 hydrazone tautomer of dye **1** are signals of H52 and H48 belonging to pyridone and hydrazone
 495 NH groups, at 12.02 and 14.58 ppm. The calculated values of these signals are at 13.03 and 14.74
 496 ppm.

497 The most significant signals for hydrazone tautomer in experimental ¹³C NMR spectrum of dye **1**
 498 are signals of two carbon atoms C5 and C7 of pyridone ring carbonyl groups, at 160.95 and 161.32
 499 ppm, respectively. Counterparts of these signals in calculated spectrum are at 167.46 and 168.86
 500 ppm. Signal at 124.04 ppm in experimental spectrum is assigned to carbon atom of C3=N2 group
 501 with calculated value of 130.84 ppm. The appearance of these signals in experimental spectrum is
 502 in a good correlation with the calculated chemical shifts for hydrazone tautomer of dye **1** which is
 503 a proof of the hydrazone structure. From Table 2 is evident that experimental and calculated
 504 chemical shifts correlate very well.

505 Table 2. Experimental and calculated ¹H NMR and ¹³C NMR chemical shifts of dye **1** in DMSO
 506 (with respect to TMS, atom positions are numbered as in Figure 3) [chemical shift (ppm)].

No.	Calc.	Exp.	No.	Calc.	Exp.
48-H	14.74	14.58	4-C	175.46	165.72
52-H	13.03	12.02	27-C	173.56	161.97
46-H	10.74	9.25	7-C	168.86	161.32
45-H	9.34	7.79	5-C	167.46	160.95
34-H	8.23	7.64	23-C	163.42	152.45
36-H	7.69	7.33	24-C	158.25	149.13
35-H	7.68	7.33	14-C	153.91	144.04
33-H	7.49	7.64	9-C	149.08	140.73
47-H	5.38	5.17	13-C	137.05	128.17
40-H	4.00	3.99	15-C	136.82	128.17

41-H	3.77	3.99	3-C	130.84	124.04
50-H	2.68	2.51	11-C	127.08	115.59
49-H	2.63	2.51	10-C	123.81	117.95
39-H	2.61	2.26	12-C	123.11	115.59
37-H	2.46	2.26	21-C	104.60	101.09
51-H	2.45	2.51	8-C	104.34	99.38
38-H	2.27	2.26	31-C	66.56	59.73
44-H	1.37	1.1	20-C	62.08	54.04
43-H	1.15	1.1	26-C	24.01	18.27
42-H	1.14	1.1	16-C	21.58	16.92
			32-C	15.55	14.58

507

508 *3.4. Calculated MEP maps of the investigated dyes*

509 In strive to reveal (re)activity toward electrophilic or nucleophilic attack for dye molecules, the
510 MEP maps on the B3LYP/6-311++G(d,p) optimized geometries are calculated. From Figure S38,
511 Supplementary material, it can be concluded that dye molecules have three possible sites for
512 electrophilic attack, according to negative regions, which exist around the oxygen atoms of
513 carbonyl groups of pyridone ring and nitrile group. Contrary, the possible sites for nucleophilic
514 attack are maximum positive regions spread around hydrogen atoms belonging to two N-H groups
515 of DHMP ring.

516 *3.5. Calculated quantum chemical descriptors for investigated dyes*

517 The massive efforts and substantial financial resources are being invested in studies of biological
518 (re)activity of the molecules. However, computational chemistry may help in such researches by
519 calculation of the biological reactivity of promising molecules [33]. In this purpose, quantum
520 chemical descriptors (QCDs) for investigated dyes **1–7** were calculated in water, employing
521 equations [33] given in Supplementary material (Equations S1-S12). The calculations of QCDs
522 have been performed in water, considering that bioassays were conducted in the aqueous solution
523 of the nutrient medium and other chemicals. Also, determination of QCDs in water can show the

524 general tendency of biological (re)activity [46] for investigated molecules. In previous
 525 publications [33, 47], it has been explained how QCDs affect biological reactivity. The calculated
 526 QCDs for the studied molecules **1–7** are given in Table S1, Supplementary material. Also, bearing
 527 in mind that dye **7** is likely to be in a zwitter ionic form, the profiling was conducted for both
 528 structures, hydrazone (**7**) and zwitter ion (**7a**). The biological reactivity of related dyes **1–7**,
 529 regarding QCDs is given in Table 3.

530 Table 3. The biological reactivity of investigated dyes regarding QCDs


Biological reactivity	
According to E_{HOMO}	$7a > 6 > 3 > 2 > 4 > 1 > 5 > 7$
According to E_{LUMO}	$5 > 7 > 1 > 4 > 2 > 3 > 6 > 7a$
According to E_{GAP}	$7a > 5 > 1 > 4 = 2 > 3 > 6 = 7$
According to I	$7a > 6 > 3 > 2 > 4 > 1 > 5 > 7$
According to A	$7a > 6 > 3 > 2 > 4 > 7 > 1 > 5$
According to η	$7a > 5 > 1 > 4 > 2 > 3 > 7 > 6$
According to σ, σ_o, S	$7a > 5 > 1 > 2 > 4 > 3 > 6 > 7$
According to χ	$5 > 7 > 1 > 4 > 2 > 3 > 6 > 7a$
According to CP	$7a > 6 > 3 > 2 > 4 > 1 > 7 > 5$
According to $\omega, N, \Delta N_{\text{max}}$	$7a > 6 > 3 > 2 > 4 > 7 > 1 > 5$

531
 532 Above results show that there is no solely sequence of reactivity, but dye molecules **7a** and **5**
 533 appear to be more biologically reactive comparing to others. It is important to note that QCDs
 534 show just the tendency of biological reactivity, and this reactivity can be changed with respect to
 535 the structure of biological target [47,48].

536 3.6. Antioxidant activity

537 Antioxidant properties of the investigated dyes have been evaluated using the ABTS assay. The
 538 scavenging activity of dyes was compared to the activity of ascorbic acid (Figure 6a). The results
 539 have shown variable activity of the compounds, indicating that substituents on the pyridone moiety
 540 affect the oxidant ability of the molecules. Namely, 3-pyridinium (**7**) and 4-phenyl substituted (**5**)
 541 dyes showed excellent (78.74% and 76.12%), and 3-amido substituted dye (**6**) expressed good

542 (62.22%) ability to scavenge the ABTS^{•+} radical cation, comparing to the inhibition of ascorbic
 543 acid (99.19%). Other investigated dyes exhibited moderate to weak antioxidant properties.
 544 The promising candidates **5**, **6** and **7** have been further evaluated by determination of IC₅₀ values,
 545 which correspond to the concentration of sample able to scavenge 50% of ABTS radicals in the
 546 solution (Figure 6b). High IC₅₀ values generally suggest low antioxidant activity. The IC₅₀ values
 547 of samples, ranged from 1.26 to 1.63 mM, indicate that investigated dyes demonstrate good
 548 antioxidant capacity comparing to IC₅₀ value of ascorbic acid (1.09 mM). Based on the comparison
 549 of the IC₅₀ values, activity of the dyes was found to be as follows: 7 > 5 > 6.
 550



551
 552 Figure 6. The antioxidant properties of investigated dyes compared to the ascorbic acid. a) The
 553 scavenging activity; b) The IC₅₀ values of dyes **5**, **6**, **7**.

554 3.7. Cytotoxic activity

555 The cytotoxic activity of **B2** and dyes **1–7** was examined against three human cancer cell lines, as
 556 well as on human normal lung fibroblasts using MTT assay (Table 4). Examination of the cytotoxic
 557 effects of the investigated compounds on human cancer cell lines showed concentration dependent
 558 cytotoxicity of all tested compounds (Table 4). Considering the cytotoxic activity of the
 559 compounds on human prostate adenocarcinoma PC-3 cells, the measured IC₅₀ values ranged from

560 48.98 μM do 194.41 μM . PC-3 cells were the most sensitive to the cytotoxicity of the compound
561 **5** (IC_{50} value of 48.98 μM). Tested compounds exerted cytotoxic effects on chronic myelogenous
562 leukemia K562 cells, with IC_{50} values of 24.97–193.32 μM . The highest intensity of the cytotoxic
563 activity on K562 cells showed compounds **5** (IC_{50} value of 24.97 μM), **3** (IC_{50} value of 41.75 μM),
564 and **6** (IC_{50} value of 55.40 μM). The compounds exhibited weaker cytotoxic activity against human
565 lung carcinoma A549 cells when compared with these activities against PC-3 and K562 cancer
566 cells. The A549 cells were the most sensitive to the cytotoxicity of the compound **5** (IC_{50} value of
567 85.16 μM). All examined compounds showed cytotoxicity against normal human lung fibroblasts
568 MRC-5, with IC_{50} values of 23.60–194.56 μM . It can be noted that assayed cancer cell lines were
569 the most sensitive to the cytotoxic effect of the compound **5**. Furthermore, **5** was selective in
570 cytotoxic action against PC-3 and K562 cells when compared with this activity against normal
571 MRC-5 cells.

572 Besides, it can be seen from Table 4, that Biginelli adduct **B2** expressed very low cytotoxic activity
573 against all investigated cancer cell lines, as well as against normal cells. This confirmed that
574 cytotoxic activity of the investigated dyes depends on the structure of pyridone moiety.
575 Furthermore, it can be noted that phenyl group on the pyridone moiety, at position C4 in the
576 structure of dye **5**, was important for the cytotoxic activity against all tested cancer cell lines.
577 However, the promising anticancer action gives compound **5** an attractive lead for further
578 structural optimization.

579 Table 4. *In vitro* cytotoxic activities of the investigated compounds [$\text{IC}_{50}^{\text{a}}$ (μM) \pm SD].

	PC-3 ^b	A549 ^b	K562 ^b	MRC-5 ^b
1	182.12 \pm 1.75	>200	191.50 \pm 12.02	179.64 \pm 11.05
2	174.60 \pm 1.12	>200	144.80 \pm 0.55	\approx 200
3	147.89 \pm 5.24	>200	41.75 \pm 1.54	42.49 \pm 1.70
4	194.41 \pm 9.18	>200	193.32 \pm 6.66	194.56 \pm 9.43
5	48.9848 \pm 1.59	85.16 \pm 6.03	24.97 \pm 0.05	91.11 \pm 5.33

6	163.21±0.97	197.82±3.09	55.40±3.56	23.60±1.98
7	181.31±9.35	191.14±12.54	133.45±4.99	176.26±3.70
B2	169.53±5.34	>200	149.10±9.53	153.66±7.26
CDDP^c	12.29 ± 1.60	12.74 ± 1.26	5.90±0.59	5.74±0.48

581 ^aCytotoxicity, IC₅₀ for each cell line, is the concentration of compound which reduced by 50% survival of treated cells
582 with respect to untreated cells using the MTT assay. ^bCell lines include human prostate adenocarcinoma (PC-3), lung
583 carcinoma (A549), chronic myelogenous leukemia (K562) and human normal lung fibroblasts MRC-5. ^cCisplatin –
584 standard reference drug.


585 3.8. Cell cycle analysis

586 The cell cycle represents an ordered series of phases that occur during the cell division [49]. The
587 main role of the cell cycle is to accomplish duplication and distribution of DNA content to newly
588 divided daughter cells. The cell cycle is consistent of G1, S, G2 and M phases. DNA replication
589 takes place in S phase, while in M phase replicated DNA is distributed to the new cells. Between
590 M and S phase there is a phase called G1 (gap 1), and between S and M phase there is another
591 phase called G2 phase (gap 2). The cells in G1 phase have normal DNA content, and cells in G2
592 phase have duplicated DNA content. All phases of the cell cycle undergo the checkpoint control,
593 which provides the cell to ensure the cell cycle progression. However, cancer cells characterize
594 the disrupted cell cycle progression, lack of the appropriate checkpoint control and the absence of
595 cell death. Thus, the initiation of the cell death in cancer cells represents an effective anticancer
596 therapy. The effect of compound **5** on the cell cycle distribution of K562 cells is studied, in order
597 to investigate its possible mechanism of action (Figure 7). To determine whether the decrease in
598 cell viability involved cell cycle distribution, cell cycle analysis was conducted by flow cytometry
599 as previously described.

600 Treatment of human myelogenous leukemia K562 cells with 2IC₅₀ concentration of the compound
601 **5** for 24 h induced increase in the percentage of cells in the subG1 phase, which is followed by the
602 increase in the percentage of cells in the G2/M phase, comparing to the control cell sample. The
603 subG1 cell population represents dead cells with reduced DNA content. Therefore, the observed

604 increase of cells within subG1 cell cycle phase appoints the ability of compound **5** to induce cell
605 death in treated K562 cells. The compound **5** also caused a cell cycle arrest of treated K562 cells
606 within G2/M phase. The observed G2/M cell cycle arrest might be due to inhibition of cells to
607 enter mitosis at G2/M checkpoint or to inhibition of cell progression through mitosis – M phase
608 arrest. These changes in treated cells were accompanied with decrease in the percentage of cells
609 within G1 and S phases. The reduced populations of treated K562 cells within G1 and S phases
610 may suggest the increased sensitivity of cells within those cell cycle phases to the cytotoxic action
611 of compound **5** [49, 50].

612 Taken together, the results of this research may suggest the possible anticancer potential of
613 compound **5**, which may serve as a starting point for development of novel antitumor agents.



614
615 Figure 7. The changes in the cell cycle phase distribution of human chronic myelogenous
616 leukemia K562 cells treated with 2IC₅₀ concentration of the compound **5** after 24 h treatment.

617
618 *3.9. In silico assessment of physicochemical and ADME properties*

619 The investigated dyes **1–7** were profiled in the computational study of physicochemical and
 620 ADME (absorption, distribution, metabolism, and excretion) properties, using SwissADME
 621 [38,51]. The physicochemical parameters and drugability of the examined compounds were
 622 evaluated with respect to the Lipinski's rule of 5 (RO5) [52]. According to the Lipinski's rule, an
 623 orally active compound has to satisfy following criteria: i) the number of hydrogen bond donors is
 624 not greater than 5 (donors being N–H and O–H groups); ii) the number of hydrogen bond acceptors
 625 is maximum 10 (acceptors being N or O atoms); iii) a molecular weight is less than 500 and iv)
 626 lipophilicity (octanol/water partition coefficient – logP) is lower than 5. When a compound
 627 violates two or more of the stated rules it will likely have poor absorption or bioavailability. The
 628 physicochemical parameters for the hydrazone tautomeric (**1–7**) and zwitter ionic (**7a**) forms,
 629 calculated by SwissADME, are presented in Table 5.

630 Table 5. The physicochemical properties of investigated compounds.

Dye	HBD ^a	HBA ^b	M log P ^c	MW ^d	Lipinski's violations ^e	%ABS ^g	Rot. Bond ^g
1	4	7	0.37	436.42	1	53.19	6
2	4	8	0.05	480.47	1	49.24	8
3	3	7	1.01	478.50	1	56.22	8
4	3	7	1.68	512.52	2	56.22	7
5	4	7	1.21	498.49	1	53.19	7
6	5	7	0.02	454.44	1	46.53	7
7	4	6	1.08	489.50	1	60.05	7
7a	3	7	1.08	488.50	1	64.21	7

631 ^aThe number of hydrogen bond donors; ^bThe number of hydrogen bond acceptors; ^cThe octanol/water partition
 632 coefficient, ^dThe molecular weight; ^eThe number of Lipinski's rule violation; ^fThe number of rotatable bonds.
 633

634 All investigated compounds, except compound **4**, can be considered as orally bioavailable, because
 635 they violate only one of the Lipinski's rule (N plus O atoms > 10, bioavailability score 0.55). The
 636 compound **4** has two violations of the stated rules (N plus O atoms > 10 and MW > 500,

637 bioavailability score 0.17) and thus, may be considered poorly orally active. It can be seen from
638 the Table 5 that parameters obtained for the both structures, **7** and **7a**, fit the Lipinski's rule.
639 Furthermore, absorption was calculated [53], and the obtained values were within the range of
640 46.53–64.21% which demonstrated that synthesized compounds have adequate cell membrane
641 permeability and bioavailability. The number of rotatable bonds is another important parameter
642 which is associated with good bioavailability. If the number of rotatable bonds is greater than 10,
643 conformational flexibility of a molecule increases and binding to a biological target is difficult.
644 The number of rotatable bonds of the investigated dyes is between 6 and 8, which indicates
645 possibility for binding to active site [54].
646 The pharmacokinetics parameters, such as blood brain barrier permeability, the ability of a
647 compound to be the P-gp (permeability glycoprotein) substrate and CYP (cytochrome enzymes)
648 inhibitor, were analyzed (Table S2, Supplementary material). All investigated compounds have
649 shown no permeation to the blood brain barrier, thus side effects to the central nervous system are
650 prevented [53]. The P-gp is a key player in the process of an active efflux through biological
651 membranes, and along with the CYPs it participates in the excretion processes [55]. All
652 investigated structures were found to be the substrates of the P-gp, except the **7**. Furthermore, the
653 pharmacokinetics parameters for CYPs inhibition have shown that novel dyes express no
654 inhibition of CYPs, excluding dye **3** and **4** which inhibit CYP2C9 enzyme.
655 Finally, the medical chemistry results, such as PAINS (pan assay interference structures) alerts
656 and synthetic accessibility scores, were analyzed (Table S2, Supplementary material). The PAINS
657 are molecules containing the moieties that often give false positive biological output [56]. Among
658 the structures under evaluation, only one structure, hydrazone tautomeric form of the **7**, displayed
659 PAINS alert. Synthetic accessibility scores of novel dyes were found to be between 4.66 and 5.02

660 (in the scale where 1 is very easy and 10 is very difficult) indicating their relatively easy
661 preparation.

662 In addition, some physicochemical descriptors such as lipophilicity (logP (Broto), lipole (Broto),
663 virtual logP), polar and apolar surface area, gyration radius, volume and ovality of the investigated
664 dyes, were estimated by Vega 22 (Table S3, Supplementary material). In contrast to SwissADME
665 evaluation, wherein mentioned descriptors have been determined based on 2D structures of
666 molecules, Vega 22 employed 3D structures of the optimized geometries, for the calculation of
667 related parameters.

668 Since lipophilicity affects pharmacodynamics action of the compound, it has the significant impact
669 on absorption, distribution, metabolism and excretion properties of the drug. The parameters
670 regarding the lipophilicity (logP (Broto), lipole (Broto), virtual logP) are given in Table S3,
671 Supplementary material. It can be concluded that all investigated compounds satisfy the principal
672 drug-like property, the $\log P < 5$, which is fundamental for the success in drug development [57].

673 **4. Conclusion**

674 In this work seven novel azo pyridone dyes based on dihydropyrimidinone scaffold have been
675 synthesized, and their structures have been confirmed experimentally and theoretically. ATR-
676 FTIR and NMR spectroscopy confirmed that obtained dyes **1–6** exist in hydrazone tautomeric
677 form, whereas dye **7** exist in zwitter ionic form, in solid state, as well as in DMSO-*d*₆ solution. The
678 conformational analysis was conducted and the optimized geometries of the most stable
679 conformers of dye **1** were obtained with B3LYP method. The largest conformational difference in
680 the molecule resulted from the rotation of the DHPM group around the C14–C20 bond. The
681 vibrational and NMR spectral analysis have shown that experimental spectra correlate well with
682 the calculated data, which was powerful confirmation of the hydrazone structure. Furthermore,

683 MEP maps revealed that the sites for the electrophilic attacks are around the carbonyl oxygen
684 atoms and nitrile group of pyridone ring, while possible sites for nucleophilic attacks are around
685 hydrogen atoms belonging to two N-H groups of DHPM. According to the calculated QCDs, the
686 molecules **7a** and **5** showed prominent reactivity. The highest antioxidant activity with respect to
687 IC_{50} value manifested dyes **5** (1.42 mM), **6** (1.63 mM) and **7** (1.26 mM), comparing to the IC_{50}
688 value of ascorbic acid (1.09 mM). Evaluation of *in vitro* cytotoxic activity of investigated
689 compounds, on human cancer cell lines PC-3, K562 and A549, showed the concentration
690 dependent cytotoxicity. The cytotoxic activity of the investigated dyes depends on the structure of
691 pyridone moiety since the Biginelli adduct **B2** expressed low cytotoxic activity against all
692 investigated cancer cell lines. All tested cancer cell lines were the most sensitive to the cytotoxic
693 action of **5**, while noticeable selectivity in cytotoxic activity is observed between human cancer
694 cell lines (PC-3 and K562) and normal (MRC-5) cells. Moreover, the cell cycle analysis of **5**,
695 examined in K562 cells, show the increase in percentage of cells within subG1 phase, which
696 indicates cell death. Also, **5** induces the cycle arrest within G2/M phase, affecting the decrease in
697 the percentage of cells within G1 and S phases, which suggests the increased sensitivity of cells to
698 the cytotoxic action of compound **5**. The ADME evaluation *in silico* has shown that all investigated
699 compounds may be orally bioavailable with no permeation to the blood brain barrier. In addition,
700 lipophilicity parameters indicate that all compounds satisfy the principal drug-like property, the
701 $\log P < 5$, which is fundamental for the success in drug development. Altogether, it can be
702 concluded that novel dyes may serve for further structural modification and development of new
703 anticancer drugs.

704 **Acknowledgement**

705 This work was supported by the Ministry of Education, Science and Technological
706 Development of the Republic of Serbia (Contract No. 451-03-68/2020-14/200287, 451-03-
707 68/2020-14/200026, 451-03-68/2020-14/200135 and 451-03-68/2020-14/200043).

708 **References**

- 709 [1] Zollinger H. Color chemistry: synthesis, properties and application of organic dyes and pigments.
710 Weinheim: Wiley-VCH; 2003.
- 711 [2] Metwally MA, Abdel-Galil E, Metwally A, Amer FA. New azodisperse dyes with thiazole, thiophene,
712 pyridone and pyrazolone moiety for dyeing polyester fabrics. *Dyes Pigments* 2012;92:902–8.
713 <https://doi.org/https://doi.org/10.1016/j.dyepig.2011.07.009>.
- 714 [3] Tao T, Zhao X, Wang Y, Qian H, Huang W. 5-Hydroxy-1-phenyl-1H-pyrazole-3-carboxylic acid based
715 heterocyclic dyes. *Dyes Pigments* 2019;166:226–32.
716 <https://doi.org/https://doi.org/10.1016/j.dyepig.2019.03.046>.
- 717 [4] Mishra VR, Ghanavatkar CW, Sekar N. UV protective heterocyclic disperse azo dyes: Spectral
718 properties, dyeing, potent antibacterial activity on dyed fabric and comparative computational study.
719 *Spectrochim Acta A* 2019;223:117353. <https://doi.org/https://doi.org/10.1016/j.saa.2019.117353>.
- 720 [5] Ali HM, Badr SQ, Temma AS. Synthesis and biological studies of some diazo dyes as new drugs. *Int J*
721 *Drug Deliv Technol* 2019;9:613–6. <https://doi.org/10.25258/ijddt.v9i4.16>.
- 722 [6] Ghasemian M, Kakanejadifard A, Azarbani F, Zabardasti A, Kakanejadifard S. Spectroscopy and
723 solvatochromism studies along with antioxidant and antibacterial activities investigation of azo-
724 azomethine compounds 2-(2-hydroxyphenylimino)methyl-4-phenyldiazenylphenol. *Spectrochim*
725 *Acta A* 2014;124:153–8. <https://doi.org/https://doi.org/10.1016/j.saa.2014.01.005>.
- 726 [7] Smith HS, Lesar TS. Analgesic prescribing errors and associated medication characteristics. *J Pain*
727 2011;12:29–40. <https://doi.org/10.1016/j.jpain.2010.04.007>.

- 728 [8] Li X, Li J, Gao Y, Kuang Y, Shi J, Xu B. Molecular Nanofibers of Olsalazine Form Supramolecular
729 Hydrogels for Reductive Release of an Anti-inflammatory Agent. *J Am Chem Soc* 2010;132:17707–
730 9. <https://doi.org/10.1021/ja109269v>.
- 731 [9] Wainwright M. Dyes in the development of drugs and pharmaceuticals. *Dyes Pigments* 2008;76:582–
732 9. <https://doi.org/https://doi.org/10.1016/j.dyepig.2007.01.015>.
- 733 [10] Afifi TH, Riyadh SM, Deawaly AA, Naqvi A. Novel chromenes and benzochromenes bearing arylazo
734 moiety: molecular docking, in-silico admet, in-vitro antimicrobial and anticancer screening. *Med*
735 *Chem Res* 2019;28:1471–87. <https://doi.org/10.1007/s00044-019-02387-5>.
- 736 [11] Ghasemi Z, Azizi S, Salehi R, Kafil HS. Synthesis of azo dyes possessing *N*-heterocycles and
737 evaluation of their anticancer and antibacterial properties. *Monatsh Chem* 2018;149:149–57.
738 <https://doi.org/10.1007/s00706-017-2073-y>.
- 739 [12] Sahoo J, Paidesetty SK. Medicinal interest of AZO-based organic compounds: A review. *Asian J*
740 *Pharm Clin Res* 2016;9:33–9.
- 741 [13] Ashkar SM, El-Asasery MA, Touma MM, Elnagdi MH. Synthesis of some novel biologically active
742 disperse dyes derived from 4-methyl-2,6-dioxo-1-propyl-1,2,5,6-tetrahydropyridine-3-carbonitrile as
743 coupling component and their colour assessment on polyester fabrics. *Molecules* 2012;17:8822–31.
744 <https://doi.org/10.3390/molecules17088822>.
- 745 [14] Karcı F, Karcı F, Demirçalı A, Yamaç M. Synthesis, solvatochromic properties and antimicrobial
746 activities of some novel pyridone-based disperse disazo dyes. *J Mol Liq* 2013;187:302–8.
747 <https://doi.org/https://doi.org/10.1016/j.molliq.2013.08.005>.
- 748 [15] Mijin D, Božić Nedeljković BB, Božić B, Kovrlija I, Ladarević J, Ušćumlić G. Synthesis,
749 solvatochromism, and biological activity of novel azo dyes bearing 2-pyridone and benzimidazole
750 moieties. *Turk J Chem* 2018;42:896–907. <https://doi.org/10.3906/kim-1711-97>.
- 751 [16] Peng Q, Li M, Gao K, Cheng L. Hydrazone-azo tautomerism of pyridone azo dyes: Part 1—NMR
752 Spectra of Tautomers. *Dyes Pigments* 1990;14:89–99. [https://doi.org/https://doi.org/10.1016/0143-
753 7208\(90\)87009-R](https://doi.org/https://doi.org/10.1016/0143-7208(90)87009-R).

- 754 [17] Peng Q, Li M, Gao K, Cheng L. Hydrazone-azo tautomerism of pyridone azo dyes: Part II:
755 Relationship between structure and pH values. *Dyes Pigments* 1991;15:263–74.
756 [https://doi.org/https://doi.org/10.1016/0143-7208\(91\)80011-W](https://doi.org/https://doi.org/10.1016/0143-7208(91)80011-W).
- 757 [18] Peng Q, Li M, Gao K, Cheng L. Hydrazone-azo tautomerism of pyridone azo dyes: Part III—effect of
758 dye structure and solvents on the dissociation of pyridone azo dyes. *Dyes Pigments* 1992;18:271–86.
759 [https://doi.org/https://doi.org/10.1016/0143-7208\(92\)80017-H](https://doi.org/https://doi.org/10.1016/0143-7208(92)80017-H).
- 760 [19] Katritzky AR, Hall CD, El-Gendy BEM, Draghici B. Tautomerism in drug discovery. *J Comput Aid*
761 *Mol Des* 2010;24:475–84. <https://doi.org/10.1007/s10822-010-9359-z>.
- 762 [20] Kappe CO. Recent Advances in the Biginelli Dihydropyrimidine Synthesis. *New Tricks from an Old*
763 *Dog. Accounts Chem Res* 2000;33:879–88. <https://doi.org/10.1021/ar000048h>.
- 764 [21] Stadler A, Kappe CO. Automated Library Generation Using Sequential Microwave-Assisted
765 Chemistry. Application toward the Biginelli Multicomponent Condensation. *J Comb Chem*
766 2001;3:624–30. <https://doi.org/10.1021/cc010044j>.
- 767 [22] de Fátima Â, Braga TC, Neto L da S, Terra BS, Oliveira BGF, da Silva DL, et al. A mini-review on
768 Biginelli adducts with notable pharmacological properties. *J Adv Res* 2015;6:363–73.
769 <https://doi.org/https://doi.org/10.1016/j.jare.2014.10.006>.
- 770 [23] Liu Y, Liu J, Zhang R, Guo Y, Wang H, Meng Q, et al. Synthesis, characterization, and anticancer
771 activities evaluation of compounds derived from 3,4-dihydropyrimidin-2(1*H*)-one. *Molecules*
772 2019;24:891–909. <https://doi.org/10.3390/molecules24050891>.
- 773 [24] Zabihollahi R, Fassihi A, Aghasadeghi MR, Memarian HR, Soleimani M, Majidzadeh-A K. Inhibitory
774 effect and structure–activity relationship of some Biginelli-type pyrimidines against HSV-1. *Med*
775 *Chem Res* 2013;22:1270–6. <https://doi.org/10.1007/s00044-012-0123-x>.
- 776 [25] Shaikh A, Meshram JS. Design, synthesis and pharmacological assay of novel azo derivatives of
777 dihydropyrimidinones. *Cogent Chem* 2015;1:1019809.
778 <https://doi.org/10.1080/23312009.2015.1019809>.

- 779 [26] Mathapati SR, Swami MB, Jadhav AH, Ghule NV, Dawle JK. Design and synthesis of classical
780 dihydropyrimidone derivatives from azosalicylaldehydes. *Der Pharma Chem* 2017;9:1–5.
- 781 [27] Matović L, Tasić N, Trišović N, Lađarević J, Vitnik V, Vitnik Ž, et al. On the azo dyes derived from
782 benzoic and cinnamic acids used as photosensitizers in dye-sensitized solar cells. *Turkish J Chem*
783 2019;43:1183–203. <https://doi.org/10.3906/kim-1903-76>.
- 784 [28] Tadić J, Mihajlović M, Jovanović M, Mijin D. Continuous flow synthesis of some 6- and 1,6-
785 substituted 3-cyano-4-methyl-2-pyridones. *J Serb Chem Soc* 2019;84:531–8.
786 <https://doi.org/10.2298/JSC180703092T>.
- 787 [29] Jiyunji T, Hiroyuki M. Preparation of 6-hydroxypyrid-2-ones. 1981. JP 56012369.
- 788 [30] Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, et al. Gaussian 09,
789 Revision D.01. Wallingford CT: Gaussian, Inc.; 2009.
- 790 [31] Andersson MP, Uvdal P. New Scale Factors for Harmonic Vibrational Frequencies Using the B3LYP
791 Density Functional Method with the Triple- ζ Basis Set 6-311+G(d,p). *J Phys Chem A* 2005;109:2937–
792 41. <https://doi.org/10.1021/jp045733a>.
- 793 [32] Dennington R, Keith T, Millam J. GaussView, Version 5.0.9. Shawnee Mission, KS: Semichem Inc.;
794 2009.
- 795 [33] Sayin K, Üngördü A. Investigations of structural, spectral and electronic properties of enrofloxacin
796 and boron complexes via quantum chemical calculation and molecular docking. *Spectrochim Acta A*
797 2019;220:117102. <https://doi.org/10.1016/j.saa.2019.05.007>.
- 798 [34] Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying
799 an improved ABTS radical cation decolorization assay. *Free Radical Biol Med* 1999;26:1231–7.
800 [https://doi.org/10.1016/S0891-5849\(98\)00315-3](https://doi.org/10.1016/S0891-5849(98)00315-3).
- 801 [35] Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and
802 cytotoxicity assays. *J Immunol Methods*. 1983;65(1–2):55–63. [https://doi.org/10.1016/0022-
803 1759\(86\)90368-6](https://doi.org/10.1016/0022-1759(86)90368-6).

- 804 [36] Ohno M, Abe T. Rapid colorimetric assay for the quantification of leukemia inhibitory factor (LIF)
805 and interleukin-6 (IL-6). *J Immunol Methods*. 1991;145(1–2):199–203. [https://doi.org/10.1016/0022-](https://doi.org/10.1016/0022-1759(91)90327-C)
806 [1759\(91\)90327-C](https://doi.org/10.1016/0022-1759(91)90327-C).
- 807 [37] Ormerod MG. *Flow cytometry. A practical approach*. Oxford University Press 2000.
- 808 [38] A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness,
809 www.swissadme.ch; Swiss Institute of Bioinformatics 2019 [accessed October 2020].
- 810 [39] Pedretti A, Villa L, Vistoli G. VEGA – An open platform to develop chemo-bio-informatics
811 applications, using plug-in architecture and script programming. *J Comput Aid Mol Des* 2004;18:167–
812 73. <https://doi.org/10.1023/B:JCAM.0000035186.90683.f2>.
- 813 [40] Mirković J, Rogan J, Poleti D, Vitnik V, Vitnik Ž, Ušćumlić G, et al. On the structures of 5-(4-, 3- and
814 2-methoxyphenylazo)-3-cyano-1-ethyl-6-hydroxy-4-methyl-2-pyridone: An experimental and
815 theoretical study. *Dyes Pigments* 2014;104:160–8.
816 <https://doi.org/https://doi.org/10.1016/j.dyepig.2014.01.007>.
- 817 [41] Mirković J, Božić B, Vitnik V, Vitnik Ž, Rogan J, Poleti D, et al. Structural, spectroscopic and
818 computational study of 5-(substituted phenylazo)-3-cyano-1-ethyl-6-hydroxy-4-methyl-2-pyridones.
819 *Color Technol* 2017;134:33–43. <https://doi.org/10.1111/cote.12321>.
- 820 [42] Mirković JM, Božić BĐ, Mutavdžić DR, Ušćumlić GS, Mijin DŽ. Solvent and structural effects on
821 the spectral shifts of 5-(substituted phenylazo)-3-cyano-6-hydroxy-1-(2-hydroxyethyl)-4-methyl-2-
822 pyridones. *Chem Phys Lett* 2014;615:62–8.
823 <https://doi.org/https://doi.org/10.1016/j.cplett.2014.09.063>.
- 824 [43] Ladarević J, Božić B, Matović L, Nedeljković BB, Mijin D. Role of the bifurcated intramolecular
825 hydrogen bond on the physico-chemical profile of the novel azo pyridone dyes. *Dyes Pigments*
826 2019;162:562–72. <https://doi.org/https://doi.org/10.1016/j.dyepig.2018.10.058>.
- 827 [44] Porobić SJ, Božić BĐ, Dramićanin MD, Vitnik V, Vitnik Ž, Marinović-Cincović M, et al. Absorption
828 and fluorescence spectral properties of azo dyes based on 3-amido-6-hydroxy-4-methyl-2-pyridone:

829 Solvent and substituent effects. *Dyes Pigments* 2020;175:108139.
830 <https://doi.org/https://doi.org/10.1016/j.dyepig.2019.108139>.

831 [45] Mijin D, Božić B, Ladarević J, Matović L, Ušćumlić G, Vitnik V, et al. Solvatochromism and quantum
832 mechanical investigation of disazo pyridone dye. *Color Technol* 2018;134:478–90.
833 <https://doi.org/10.1111/cote.12369>.

834 [46] Sayin K, Kariper SE, Taştan M, Sayin TA, Karakaş D. Investigations of structural, spectral, electronic
835 and biological properties of *N*-heterocyclic carbene Ag(I) and Pd(II) complexes. *J Mol Struct* 2019;
836 1176:478-487. <https://doi.org/10.1016/j.molstruc.2018.08.103>.

837 [47] Erkan S. Activity of the rocuronium molecule and its derivatives: A theoretical calculation. *J Mol*
838 *Struct* 2019;1189:257–64. <https://doi.org/10.1016/j.molstruc.2019.04.042>.

839 [48] Kökbudak Z, Saracoglu M, Akkoç S, Çimen Z, Yilmazer MI, Kandemirli F. Synthesis, cytotoxic
840 activity and quantum chemical calculations of new 7-thioxopyrazolo[1,5-f]pyrimidin-2-one
841 derivatives. *J Mol Struct* 2020;1202:127261. <https://doi.org/10.1016/j.molstruc.2019.127261>.

842 [49] Mukherjee S, Mitra I, Reddy V, Fouzder C, Mukherjee S, Ghosh S, et al. Effect of Pt(II) complexes
843 on cancer and normal cells compared to clinically used anticancer drugs: cell cycle analysis, apoptosis
844 and DNA/BSA binding study. *J Mol Liq* 2017;247:126–40.
845 <https://doi.org/10.1016/j.molliq.2017.09.104>.

846 [50] Keleş T, Barut B, Özel A, Biyiklioglu Z. Synthesis of water soluble silicon phthalocyanine,
847 naphthalocyanine bearing pyridine groups and investigation of their DNA interaction, topoisomerase
848 inhibition, cytotoxic effects and cell cycle arrest properties. *Dyes Pigments* 2019;164:372–83.
849 <https://doi.org/10.1016/j.dyepig.2019.01.044>.

850 [51] Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-
851 likeness and medicinal chemistry friendliness of small molecules. *Sci Rep* 2017;7:42717.
852 <https://doi.org/10.1038/srep42717>.

- 853 [52] Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to
854 estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliver*
855 *Rev* 1997;23:3–25. [https://doi.org/https://doi.org/10.1016/S0169-409X\(96\)00423-1](https://doi.org/https://doi.org/10.1016/S0169-409X(96)00423-1).
- 856 [53] Ismail MMF, Farrag AM, Harras MF, Ibrahim MH, Mehany ABM. Apoptosis: A target for anticancer
857 therapy with novel cyanopyridines. *Bioorg Chem* 2020;94:103481.
858 <https://doi.org/10.1016/j.bioorg.2019.103481>.
- 859 [54] Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular Properties That
860 Influence the Oral Bioavailability of Drug Candidates. *J Med Chem* 2002;45:2615–23.
861 <https://doi.org/10.1021/jm020017n>.
- 862 [55] Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al. Interrelationship between
863 substrates and inhibitors of human CYP3A and P-glycoprotein. *Pharm Res.* 1999;16:408–14. doi:
864 10.1023/a:1018877803319.
- 865 [56] Jonathan BB, Georgina AH. New Substructure Filters for Removal of Pan Assay Interference
866 Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. *J Med Chem*
867 2010;53:2719–40. doi: 10.1021/jm901137j.
- 868 [57] Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal
869 chemistry. *Nat Rev Drug Discov* 2007;6:881–90. doi: 10.1038/nrd2445.